Skip to main content

March 2017, Vol 10, Eighth Annual Payers' Guide

Payers' Guide, FDA Approvals
Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Xeljanz XR (Tofacitinib) First Once-Daily Oral JAK Inhibitor Approved for Patients with Rheumatoid Arthritis
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Innovation Continues to Drive Drug Development, Even as FDA Approvals Drop in 2016
Dalia Buffery, MA, ABD
Read More
Payers' Guide, FDA Approvals
Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
Read More
Page 2 of 2
Results 11 - 14 of 14